 |
Top 16 Brain cancer treatment startups
Oct 25, 2025 | By Jason Kwon | 28 |
These startups develop new brain cancer (Glioblastoma, Neuroblastoma ...) treatments and diagnostics technologies, such as stereotactic radiosurgery, targeted therapy, immunotherapy, AI genome analytics, surgery robotics.
1
Country: Israel | Funding: $1B
Novocure is an oncology company pioneering a novel therapy for solid tumors called Tumor Treating Fields, or TTFields. TTFields are low intensity, alternating electric fields within the intermediate frequency range. TTFields disrupt cell division through physical interactions with key molecules during mitosis. This non-invasive treatment targets solid tumors.
Novocure is an oncology company pioneering a novel therapy for solid tumors called Tumor Treating Fields, or TTFields. TTFields are low intensity, alternating electric fields within the intermediate frequency range. TTFields disrupt cell division through physical interactions with key molecules during mitosis. This non-invasive treatment targets solid tumors.
2
Country: USA | Funding: $614.6M
Neumora Therapeutics is pioneering a new era of precision medicines for Brain Diseases
Neumora Therapeutics is pioneering a new era of precision medicines for Brain Diseases
3
Country: USA | Funding: $337M
Ziopharm oncology is a biotechnology company that acquires, develops, and commercializes cancer therapies.
Ziopharm oncology is a biotechnology company that acquires, develops, and commercializes cancer therapies.
4
Country: USA | Funding: $253.7M
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
Imvax is a biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies.
5
Country: USA | Funding: $95M
Lantern Pharma is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action.
Lantern Pharma is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action.
6
Country: USA | Funding: $65M
Actuate Therapeutics is a biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis and neurodegeneration. Our work has led to some fascinating results around anti-tumor activity in the brain, pancreas, lungs, and breasts.
Actuate Therapeutics is a biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis and neurodegeneration. Our work has led to some fascinating results around anti-tumor activity in the brain, pancreas, lungs, and breasts.
7
Country: UK | Funding: $6.8M
Longer, Better Quality Lives for Brain Tumour Patients
Longer, Better Quality Lives for Brain Tumour Patients
8
Country: USA | Funding: $3.5M
OX2 Therapeutics is a healthcare therapeutics company that focuses on treating brain tumors.
OX2 Therapeutics is a healthcare therapeutics company that focuses on treating brain tumors.
9
Country: USA | Funding: $625K
Accuronix Therapeutics is a biotech company that develops drug targeting technology to resolve issues in cancer therapy. The startup’s lead candidate ACXT-3102, enables effective ligand binding to deliver targeted cytotoxic payloads in patients suffering from pancreatic adenocarcinoma. Accuronix also is developing MTDCs for other types of cancers such as breast or brain cancer.
Accuronix Therapeutics is a biotech company that develops drug targeting technology to resolve issues in cancer therapy. The startup’s lead candidate ACXT-3102, enables effective ligand binding to deliver targeted cytotoxic payloads in patients suffering from pancreatic adenocarcinoma. Accuronix also is developing MTDCs for other types of cancers such as breast or brain cancer.
10
Country: Sweden | Funding: €71.4K
Our mission is to bring value to every patient by maximizing the capacity of some of the most effective medicines known and make them even better. Our areas of expertise are brain cancer, liver cancer and pneumonia. We have developed ways to treat these diseases much more effectively with our drug delivery system.
Our mission is to bring value to every patient by maximizing the capacity of some of the most effective medicines known and make them even better. Our areas of expertise are brain cancer, liver cancer and pneumonia. We have developed ways to treat these diseases much more effectively with our drug delivery system.
11
Country: UK
GlioQuell is a biopharmaceutical company dedicated to developing technologies and therapeutics targeting cellular bioenergetics. Based on cutting-edge proprietary science, the company is discovering and developing novel therapeutics for treating refractory brain tumours and other diseases with significant medical and societal burden.
GlioQuell is a biopharmaceutical company dedicated to developing technologies and therapeutics targeting cellular bioenergetics. Based on cutting-edge proprietary science, the company is discovering and developing novel therapeutics for treating refractory brain tumours and other diseases with significant medical and societal burden.
12
Country: UK
Theragnostics develops fluorine-18 based radiopharmaceuticals. THG-008, the startup’s lead drug, is a fluorine-18 radiolabelled poly-ADP-ribose polymerase (PARP) inhibitor (rPARPi). It aids in head and neck cancer, as well as brain cancer imaging.
Theragnostics develops fluorine-18 based radiopharmaceuticals. THG-008, the startup’s lead drug, is a fluorine-18 radiolabelled poly-ADP-ribose polymerase (PARP) inhibitor (rPARPi). It aids in head and neck cancer, as well as brain cancer imaging.
★
See also:
